Guillain-Barré Syndrome Market Insights, Epidemiology and Market Forecast-2028

Albany, NY -- (SBWire) -- 11/07/2019 --Guillain-Barré Syndrome Market Insights, Epidemiology and Market Forecast-2028

1. Guillain-Barré Syndrome incidence in children (0–15 years old) was found to be 0.34 and 1.34/100,000.
2. In Europe and North America similar Guillain-Barré Syndrome annual incidence rates were reported, i.e. between 0.84 and 1.91/10,000
3. in Japan, Guillain-Barré Syndrome incidence was 1.15 per 100,000 person-years.

(Albany, US) DelveInsight launched a new report on Guillain-Barré Syndrome Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Guillain-Barré Syndrome market report covers a descriptive overview and comprehensive insight of the Guillain-Barré Syndrome epidemiology and Guillain-Barré Syndrome market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Guillain-Barré Syndrome market report provides insights into current and emerging therapies.
3. Guillain-Barré Syndrome market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Guillain-Barré Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and leading the Guillain-Barré Syndrome market.

Request for sample pages

"Males were affected 1.5 times more frequently than females."

Guillain-Barré syndrome is a rapidly progressive and potentially life-threatening polyradiculoneuropathy that requires early diagnosis, monitoring and treatment. The progress of the disorder is very comokex to foretell. Many people are diagnosed with Guillain-Barré syndrome, hospitalised for any complications, which might affect their vital functions can be treated promptly.
The current mainstays for Guillain-Barré syndrome treatment includes the use of symptomatic medical care to restore breathing ability, immunotherapy, and rehabilitation to restore movement and muscle strength. The symptomatic medical care to relieve the disease associated symptoms include the use of Antihypertensives (with short half-lives) such as Trandate (labetolol; Prometheus Laboratories), esmolol (WG Critical Care), or nitroprusside to relieve hypertension. Furthermore, beta-adrenergic or calcium channel blockers are also being prescribed, especially if episodes of hypertension alternate with hypotension. Percutaneous dilatational tracheostomy may be beneficial over traditional tracheostomy and allows less risk of accidental extubation and a better cosmetic outcome for respiratory failure.
For the prevention of deep vein thrombosis, subcutaneous fractionated or unfractionated heparin and support stockings are being recommended until patients are able to walk independently to prevent deep vein thrombosis.
The diagnosis, prognosis, and management of Guillain-Barré syndrome persist to be difficult in current practice. This is in relation to an incomplete comprehension of the pathophysiology of the disease process, complexity of initiating factors, and a lack of evidence-based standardized therapies. Companies have recently shifted their focus towards the development of new Guillain-Barré syndrome therapeutic options. The Guillain-Barré syndrome market is expected to experience a positive growth in the coming years owing to the already prescribed products along with the launch of distinctive emerging therapies in coming years.
.
The launch of the emerging therapies is expected to significantly impact Guillain-Barré Syndrome treatment scenario in the upcoming years: -
Drugs covered
1. ANX005
2. Imlifidase
3. And many others

The key players in Guillain-Barré Syndrome market are:
1. Hansa Medical
2. Cellenkos
3. Annexon Biosciences
4. Akari Therapeutics
And many others

Table of contents

1. Report Introduction
2. Guillain-Barré Syndrome Market Overview at a Glance
3. Guillain-Barré Syndrome Disease Background and Overview
4. Guillain-Barré Syndrome Epidemiology and Patient Population
5. Guillain-Barré Syndrome Epidemiology by Countries (2017-2028)
5.1. United States- Epidemiology (2017-2028)
5.2. EU-5 - Epidemiology (2017-2028)
5.3. Germany-Epidemiology (2017-2028)
5.4. France-Epidemiology (2017-2028)
5.5. Italy-Epidemiology (2017-2028)
5.6. Spain-Epidemiology (2017-2028)
5.7. United Kingdom-Epidemiology (2017-2028)
5.8. Japan-Epidemiology (2017-2028)
6. Guillain-Barré Syndrome Treatments & Medical Practices
7. Guillain-Barré Syndrome Marketed Therapies
7.1. Gamunex: Grifols
7.2. Intratect: Biotest AG
7.3. Kenketu Glovenin: Nihon Pharmaceutical
8. Guillain-Barré Syndrome Emerging Therapies
8.1. Key Cross Competition
8.2. ANX005 : Annexon Biosciences
8.3. Imlifidase : Hansa Medical
9. Guillain-Barré Syndrome Market Size
10. 7MM: Country-Wise Market Analysis
10.1.United States Market Size
10. 7MM: Country-Wise Market Analysis
10.1.United States Market Size
10.2.Germany Market Size
10.3. France Market Size
10.4.Italy Market Size
10.5. Spain Market Size
10.6.United Kingdom Market Size
10.7.Japan Market Size
11. Market Drivers
12. Market Barriers
13. Report Methodology
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.